Showing results (3271-3280 of 3,354) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|February 27, 2026
Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder GroupOlena Mandrik, Chloe Thomas, Alice Bessey, et al.Pharmacoeconomics|April 2, 2026
What is the Value of Developing an HTA Process?Peter Murphy, Simon Walker, Septiara Putri, et al.Pharmacoeconomics|March 18, 2026
A Modern Approach for Constructing Decision Analytic Models in Microsoft ExcelMike PauldenPharmacoeconomics|May 5, 2026
Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial HypertensionAdnan Alsumali, Vasco M Pontinha, Benjamin G Cohen, et al.Pharmacoeconomics|April 22, 2018
Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value SetsBrendan Mulhern, Yan Feng, Koonal Shah, et al.Pharmacoeconomics|May 27, 1999
Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantationA J Coukell, G L PloskerPharmacoeconomics|July 27, 2002
Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosisJ Jaime Caro, Denis Getsios, Ingrid Caro, et al.Pharmacoeconomics|May 26, 2026
Identifying and Comparing Intervention Cost Components in Remote Patient Monitoring: A Scoping ReviewAnna L Heilig, Wilbert B van den Hout, M Elske van den Akker-van MarlePharmacoeconomics|May 26, 2026
Real-World Economic Burden Associated with Progressive Pulmonary Fibrosis in the US: An Administrative Claims Database AnalysisJoseph Yang, Bonnie H Bui, Tim Bancroft, et al.Pharmacoeconomics|January 26, 2007
Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccineDavid Bishai, Roger Brice, Isabelle Girod, et al.Pageof 336